EGRX News and Press, Eagle Pharmaceuticals Inc. From 07/28/22

WOODCLIFF LAKE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 second quarter financial results on Tuesday, August 9, 2022, before the market ope...

WOODCLIFF LAKE, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the appointment of Debra M. Hussain as Senior Vice President, Head of Commercial. “We are very pleased with ...

Adds two U.S. Food and Drug Administration (“FDA”) approved new chemical entities with strong patent protection BARHEMSYS ® (amisulpride for injection) and BYFAVO ® (remimazolam for injection) join Eagle portfolio, with an estimated combined $3.1 bill...

Eagle Pharmaceuticals' (NASDAQ:EGRX) said its licensing partner AOP Orphan Pharmaceuticals submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of landiolol for a type of heart disorder. The filing seeks approval of landiolol for the short-ter...

-- Submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter -- -- Expected approval mid-year 2023, if accepted by FDA for filing, based on feedback from U.S. F...

WOODCLIFF LAKE, N.J., May 26, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the William Blair 42nd Annual Growt...

Second quarter guidance implies catastrophic sales and margins from Vasostrict. Bonds plummeted implying first lien debt might be impaired. Possibly impairment of first lien debt and near certain impairment of second lien debt means zero equity value. Bankruptcy filing should ...

Image source: The Motley Fool. Eagle Pharmaceuticals (NASDAQ: EGRX) Q1 2022 Earnings Call May 09, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Eagle Pharmaceuticals (EGRX) Q1 2022 Earnings Call Transcript

Eagle Pharmaceuticals, Inc. (EGRX) Q1 2022 Earnings Conference Call May 09, 2022, 08:30 ET Company Participants Lisa Wilson - IR Scott Tarriff - Founder, President, CEO & Director Brian Cahill - CFO Conference Call Participants Brandon Folkes - Cantor Fitzgerald & Co. Lachlan Hanbury-...

Eagle Pharmaceuticals press release (NASDAQ:EGRX): Q1 Non-GAAP EPS of $3.41 misses by $0.25. Revenue of $115.9M (+181.0% Y/Y) misses by $7.53M. For further details see: Eagle Pharmaceuticals Non-GAAP EPS of $3.41 misses by $0.25, revenue of $115.9M misses by $7.53M